Nkarta Q2 2026: cash $243.2M, net loss $40.4M; NKX019 trials advance

Nkarta, Inc.

Cash, equivalents, restricted cash and investments $243.2M as of June 30, 2026; expected to fund operations into 2029.
Q2 2026 net loss $40.4M ($0.54 per share); R&D expense $29.0M, G&A expense $14.1M.
Enrollment continues across Ntrust-1 and Ntrust-2 at 4B cells/dose (12B total) in all autoimmune indications.
Outpatient dosing underway at community sites after FDA agreement; initial Ntrust data expected at 2026 medical conference.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.